Drug Trial Radar · NCT06786286
A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects
Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jan 28, 2025
Primary completion
Mar 26, 2025
Study completion Mar 26, 2025
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 30 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
ITI-1284-012 is an open-label, single-dose study to assess the mass balance recovery of radioactivity, and to evaluate the pharmacokinetics, safety and tolerability of ITI-1284 after a single subcutaneous dose of \[14C\]-ITI-1284 in healthy male subjects.
Conditions
- Healthy Volunteers
Interventions
[14C]-ITI-1284Drug
\[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mass balance recovery of total radioactivity in urine and feces combinedTime frame: Day 1 up to Day 29
- Pharmacokinetics: AUC0-t for total radioactivityTime frame: Day 1 up to Day 29
- Pharmacokinetics: AUC0-t for ITI-1284Time frame: Day 1 to Day 8
- Pharmacokinetics: Cmax for total radioactivityTime frame: Day 1 up to Day 29
- Pharmacokinetics: Cmax for ITI-1284Time frame: Day 1 to Day 8
- Pharmacokinetics: Tmax for total radioactivityTime frame: Day 1 up to Day 29
- Pharmacokinetics: Tmax for ITI-1284Time frame: Day 1 to Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Site 1
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.